1
|
Abdelaziz R, Di Trani JM, Sahile H, Mann L, Richter A, Liu Z, Bueler SA, Cowen LE, Rubinstein JL, Imming P. Imidazopyridine Amides: Synthesis, Mycobacterium smegmatis CIII 2CIV 2 Supercomplex Binding, and In Vitro Antimycobacterial Activity. ACS OMEGA 2023; 8:19081-19098. [PMID: 37273644 PMCID: PMC10233671 DOI: 10.1021/acsomega.3c02259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 04/18/2023] [Indexed: 06/06/2023]
Abstract
Q203 (telacebec) is an imidazopyridine amide (IPA) targeting the respiratory CIII2CIV2 supercomplex of the mycobacterial electron transport chain (ETC). Aiming for a better understanding of the molecular mechanism of action of IPA, 27 analogues were prepared through a seven-step synthetic scheme. Oxygen consumption assay was designed to test the inhibition of purified Mycobacterium smegmatis CIII2CIV2 by these compounds. The assay results generally supported structure-activity relationship information obtained from the structure of M. smegmatis CIII2CIV2 bound to Q203. The IC50 of Q203 and compound 27 was 99 ± 32 and 441 ± 138 nM, respectively. All IPAs including Q203 showed no inhibition of mitochondrial ETC, proving their selectivity against mycobacteria. In vitro Mycobacterium tuberculosis growth inhibition and M. smegmatis CIII2CIV2 binding did not correlate perfectly. These observations suggest that further investigation into the mechanisms of resistance in different mycobacterial species is needed to understand the lack of the correlation pattern between CIII2CIV2 inhibition and cellular activity.
Collapse
Affiliation(s)
- Rana Abdelaziz
- Institut
Für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany
| | - Justin M Di Trani
- Molecular
Medicine Program, The Hospital for Sick
Children, Toronto M5G 0A4, Canada
| | - Henok Sahile
- Departments
of Medicine and Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver V6T 1Z3, Canada
| | - Lea Mann
- Institut
Für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany
| | - Adrian Richter
- Institut
Für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany
| | - Zhongle Liu
- Department
of Molecular Genetics, The University of
Toronto, Toronto M5G 0A4, Canada
| | - Stephanie A. Bueler
- Molecular
Medicine Program, The Hospital for Sick
Children, Toronto M5G 0A4, Canada
| | - Leah E. Cowen
- Department
of Molecular Genetics, The University of
Toronto, Toronto M5G 0A4, Canada
| | - John L. Rubinstein
- Molecular
Medicine Program, The Hospital for Sick
Children, Toronto M5G 0A4, Canada
- Department
of Medical Biophysics, The University of
Toronto, Toronto M5G 0A4, Canada
- Department
of Biochemistry, The University of Toronto, Toronto M5G 0A4, Canada
| | - Peter Imming
- Institut
Für Pharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale) 06120, Germany
| |
Collapse
|
2
|
Mi J, Gong W, Wu X. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis. BIOMED RESEARCH INTERNATIONAL 2022; 2022:5099312. [PMID: 35252448 PMCID: PMC8896939 DOI: 10.1155/2022/5099312] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/03/2021] [Accepted: 02/14/2022] [Indexed: 12/15/2022]
Abstract
Tuberculosis (TB) is a severe infectious disease worldwide. The increasing emergence of drug-resistant Mycobacterium tuberculosis (Mtb) has markedly hampered TB control. Therefore, there is an urgent need to develop new anti-TB drugs to treat drug-resistant TB and shorten the standard therapy. The discovery of targets of drug action will lay a theoretical foundation for new drug development. With the development of molecular biology and the success of Mtb genome sequencing, great progress has been made in the discovery of new targets and their relevant inhibitors. In this review, we summarized 45 important drug targets and 15 new drugs that are currently being tested in clinical stages and several prospective molecules that are still at the level of preclinical studies. A comprehensive understanding of the drug targets of Mtb can provide extensive insights into the development of safer and more efficient drugs and may contribute new ideas for TB control and treatment.
Collapse
Affiliation(s)
- Jie Mi
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing 100091, China
| | - Wenping Gong
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing 100091, China
| | - Xueqiong Wu
- Tuberculosis Prevention and Control Key Laboratory/Beijing Key Laboratory of New Techniques of Tuberculosis Diagnosis and Treatment, Senior Department of Tuberculosis, The 8th Medical Center of PLA General Hospital, Beijing 100091, China
| |
Collapse
|